目的 探讨复方脑肽节苷脂联合依达拉奉治疗急性脑梗死的临床疗效以及其对患者血清中枢神经特异性蛋白（S100β）、神经元特异性烯醇化酶（NSE）、8异前列腺素F_2α（8-iso-PGF_2α）和丙二醛（MDA）水平的影响。方法 选取2018年1月-2019年12月山东省蓬莱市人民医院收治的120例急性脑梗死患者作为研究对象，按照治疗方法将患者分成对照组（n=60）和观察组（n=60）。对照组患者静脉滴注依达拉奉注射液，将30 mg加入250 mL生理盐水中均匀混合后给药，2次/d。观察组在对照组的基础上静脉滴注复方脑肽节苷脂注射液，将10 mL加入250 mL生理盐水中充分稀释后给药，1次/d。两组连续治疗14 d。观察两组患者的临床疗效，同时比较两组治疗前后的美国国立卫生研究院卒中量表（NIHSS）评分、脑卒中专门化生活质量量表（SS-QOL）评分，以及血清S100β、NSE、8-iso-PGF_2α和MDA水平。结果 治疗后，观察组总有效率为95.0%，显著高于对照组的81.7%（P<0.05）。治疗后，两组NIHSS评分均显著降低，SS-QOL评分则均显著升高（P<0.05）；观察组NIHSS和SS-QOL评分显著优于对照组（P<0.05）。治疗后，两组血清S100β、NSE、8-iso-PGF_2α和MDA水平均显著低于治疗前（P<0.05），且观察组血清S100β、NSE、8-iso-PGF_2α和MDA水平显著低于对照组（P<0.05）。结论 复方脑肽节苷脂联合依达拉奉对急性脑梗死患者具有确切的临床疗效，对患者脑神经损伤、神经功能缺损及生存质量均有明显改善作用，可进一步降低血中8-iso-PGF_2α、MDA的水平，且安全性较好。

Objective To investigate the clinical efficacy of compound brain peptide glycoside combined with edaravone in treatment of acute cerebral infarction and its effect on patients' serum levels of S100β, NSE, 8-iso-PGF_2α, and MDA. Methods A total of 120 patients with acute cerebral infarction admitted to Penglai People's Hospital of Shandong Province from January 2018 to December 2019 were selected as the research subjects, and the patients were divided into control group (n=60) and observation group (n=60) according to the treatment methods. Patients in the control group was intravenously injected with Edaravone Injection, 30 mg was added into 250 mL normal saline, and then evenly mixed, twice daily. Patients in the observation group was additionally injected with Compound Porcine Cerebroside and Ganglioside Injection intravenously, adding 10 mL into 250 mL normal saline and giving the injection after full dilution, once daily. Two groups were treated continuously for 14 days. Clinical efficacy of two groups was observed. The NIHSS score, SS-QOL score, serum S100β, NSE, 8-iso-PGF_2α, and MDA levels before and after treatment were compared between two groups. Results After treatment, the total effective rate of observation group was 95.0%, significantly higher than 81.7% of control group (P<0.05). After treatment, NIHSS score in two groups was significantly decreased, while SS-QOL score was increased (P<0.05). And NIHSS and SS-QOL scores in the observation group were significantly better than those in the control group (P<0.05). After treatment, the serum levels of S100β, NSE, 8-iso-PGF_2α, and MDA in two groups were significantly lower than those before treatment (P<0.05), and the serum levels of S100β, NSE, 8-iso-PGF_2α, and MDA in observation group were significantly lower than those in control group (P<0.05). Conclusions Compound brain peptide glycoside combined with edaravone has a definite clinical effect on patients with acute cerebral infarction, and can significantly improve the brain nerve injury, neurological function deficit and quality of life of patients, and can further reduce the levels of 8-iso-PGF_2αand MDA in blood, with good safety.

R971